Coherus Biosciences Inc (CHRS) : Rhenman Partners Asset Management Ab added new position in Coherus Biosciences Inc during the most recent quarter end. The investment management firm now holds 131,357 shares of Coherus Biosciences Inc which is valued at $3,667,487 , the company said in a statement filed on Aug 1, 2016 with the SEC.Coherus Biosciences Inc makes up approximately 0.59% of Rhenman Partners Asset Management Ab’s portfolio.
Other Hedge Funds, Including , Cam Group Holding As boosted its stake in CHRS in the latest quarter, The investment management firm added 2,500 additional shares and now holds a total of 151,000 shares of Coherus Biosciences Inc which is valued at $3,833,890. Coherus Biosciences Inc makes up approx 0.07% of Cam Group Holding As’s portfolio.Handelsbanken Fonder Ab reduced its stake in CHRS by selling 10,000 shares or 18.18% in the most recent quarter. The Hedge Fund company now holds 45,000 shares of CHRS which is valued at $1,054,800. Coherus Biosciences Inc makes up approx 0.04% of Handelsbanken Fonder Ab’s portfolio.Mazama Capital Management Inc boosted its stake in CHRS in the latest quarter, The investment management firm added 63 additional shares and now holds a total of 1,366 shares of Coherus Biosciences Inc which is valued at $23,523.
Coherus Biosciences Inc opened for trading at $27.92 and hit $28.35 on the upside on Thursday, eventually ending the session at $28.09, with a gain of 0.61% or 0.17 points. The heightened volatility saw the trading volume jump to 2,26,443 shares. Company has a market cap of $1,099 M.
Many Wall Street Analysts have commented on Coherus Biosciences Inc. Citigroup Initiated Coherus Biosciences Inc on Jul 27, 2016 to “Buy”, Price Target of the shares are set at $36.
Coherus BioSciences Inc. is a late-stage clinical biologics platform company focused on the global biosimilar market. The Company’s clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor (TNF) and a long-acting form of granulocyte colony-stimulating factor (G-CSF). The Company’s product pipeline includes anti-TNF product candidate CHS-0214 an etanercept (Enbrel) biosimilar candidate which is in Phase III clinical trials and anti-TNF product candidate CHS-1420 an adalimumab (Humira) biosimilar candidate which is in Phase III clinical trials. The Company also offers G-CSF product candidate CHS-1701 a pegfilgrastim (Neulasta) biosimilar which has completed a Phase I study.